Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Nivolumab (Primary) ; Rucaparib (Primary)
- Indications Adenocarcinoma; Biliary cancer; Gallbladder cancer
- Focus Therapeutic Use
- 07 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Feb 2019.
- 03 Dec 2018 Planned End Date changed from 1 Oct 2021 to 1 Jan 2022.
- 03 Dec 2018 Planned primary completion date changed from 1 Oct 2021 to 1 Jan 2022.